New ALS treatment enters human testing in global program

Trace Neuroscience has launched its clinical development program for TRCN-1023, an experimental treatment for amyotrophic lateral sclerosis (ALS) that is designed to restore the function of UNC13A, a protein involved in nerve-muscle communication. The global clinical program includes FUNCTION ALS, a company-sponsored Phase 1/2 clinical trial authorized…

I’m writing this column from vacation in a place I once traveled with my late husband, Jeff, long before he was diagnosed with ALS in 2018. It was a dream trip of his, and we went together for his birthday more than a decade ago. On this trip, we…

The lowest tested dose of Amylyx Pharmaceuticals‘ treatment candidate AMX0114 was found to be safe and well tolerated among people with amyotrophic lateral sclerosis (ALS) in an ongoing Phase 1 clinical trial. Biomarkers of nerve damage due to ALS remained relatively stable from the study’s start — a result…

A couple months ago, I planted zinnia and strawflower seeds in two plastic bins and set them in the sunlight under our patio window in my dining room. I’ve grown vegetables from seeds in the past, but never flowers. Vegetables feel practical because food is necessary to sustain life, while…

The first patient has been dosed in a Phase 1/2 clinical trial evaluating Leal Therapeutics‘ LTX-002, an antisense oligonucleotide designed to target abnormalities in fat metabolism that may contribute to amyotrophic lateral sclerosis (ALS). The NeurALS trial (NCT07660614) is now recruiting an estimated 56 adults with ALS at…

Nura Bio has raised $73.8 million to support two experimental therapies designed to protect nerve cells from damage, including one that is already being tested in people with amyotrophic lateral sclerosis (ALS). Proceeds from the Series B financing round, usually the second major funding round for…

Treatment burden — the workload associated with managing a disease, including taking medications, attending medical appointments, and carrying out self-care tasks — was reported by nearly 70% of patients with amyotrophic lateral sclerosis (ALS), according to a study in Italy. Among patients reporting any burden, more than half were…

Lower blood levels of adiponectin, a signaling molecule produced by fat tissue, and the anti-inflammatory molecule interleukin (IL)-10 are associated with faster disease progression and shorter survival in people with amyotrophic lateral sclerosis (ALS), a study in China found. The findings also showed that established prognostic measures, such as…

I’ve recently started meeting with a therapist through telehealth to try to better cope with life as my husband’s caregiver. Todd is homebound now, so we have been more isolated, which is hard on my mental health. It’s stressful to always be on duty, ready to move an arm,…

Projenx‘s prosetin was found to be safe and well tolerated at doses that engaged its therapeutic target in people with amyotrophic lateral sclerosis (ALS), supporting its continued development as a potential disease-modifying therapy. These interim data from the fully enrolled PRO-101 Phase 1 clinical trial (NCT05279755), including…